Concourse Financial Group Securities, Inc. Biomarin Pharmaceutical Inc Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

A detailed history of Concourse Financial Group Securities, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 15 shares of BMRN stock, worth $999. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 51 70.59%

Holding current value

$999

Previous $4,000 75.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$69.02 - $93.84 $2,484 - $3,378	-36 Reduced 70.59%	15 $1,000
Q2 2024 Jul 23, 2024	SELL	$74.43 - $92.22 $330,245 - $409,180	-4,437 Reduced 98.86%	51 $4,000
Q1 2024 Apr 30, 2024	BUY	$83.81 - $99.0 $21,036 - $24,849	251 Added 5.92%	4,488 $391,000
Q4 2023 Feb 07, 2024	SELL	$76.22 - $98.51 $17,911 - $23,149	-235 Reduced 5.25%	4,237 $408,000
Q3 2023 Oct 25, 2023	BUY	$85.07 - $94.48 $24,840 - $27,588	292 Added 6.99%	4,472 $395,000
Q2 2023 Aug 10, 2023	BUY	$86.68 - $100.3 $39,352 - $45,536	454 Added 12.18%	4,180 $362,000
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $97,566 - $130,404	1,112 Added 42.54%	3,726 $362,000
Q4 2022 Jan 30, 2023	SELL	$80.93 - $108.63 $32,372 - $43,452	-400 Reduced 13.27%	2,614 $0
Q3 2022 Nov 15, 2022	SELL	$82.16 - $96.94 $11,584 - $13,668	-141 Reduced 4.47%	3,014 $255,000
Q2 2022 Aug 09, 2022	SELL	$71.48 - $86.85 $140,529 - $170,747	-1,966 Reduced 38.39%	3,155 $261,000
Q1 2022 May 09, 2022	SELL	$74.28 - $92.69 $391,752 - $488,847	-5,274 Reduced 50.74%	5,121 $395,000
Q4 2021 Feb 07, 2022	BUY	$71.72 - $91.47 $22,089 - $28,172	308 Added 3.05%	10,395 $918,000
Q3 2021 Nov 09, 2021	BUY	$74.77 - $85.47 $96,154 - $109,914	1,286 Added 14.61%	10,087 $780,000
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $114,171 - $128,202	1,512 Added 20.74%	8,801 $734,000
Q1 2021 May 13, 2021	BUY	$74.73 - $90.69 $357,732 - $434,133	4,787 Added 191.33%	7,289 $550,000
Q4 2020 Feb 02, 2021	BUY	$72.61 - $90.2 $102,234 - $127,001	1,408 Added 128.7%	2,502 $219,000
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $70,935 - $129,326	987 Added 922.43%	1,094 $83,000
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $1,591 - $2,484	20 Added 22.99%	107 $13,000
Q1 2020 May 13, 2020	BUY	$71.37 - $96.85 $642 - $871	9 Added 11.54%	87 $7,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $3,149 - $4,232	49 Added 168.97%	78 $7,000
Q3 2019 Nov 13, 2019	SELL	$67.4 - $85.11 $36,193 - $45,704	-537 Reduced 94.88%	29 $2,000
Q2 2019 Aug 13, 2019	BUY	$80.35 - $93.9 $31,095 - $36,339	387 Added 216.2%	566 $48,000
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $5,809 - $6,804	69 Added 62.73%	179 $15,000
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $4,087 - $5,409	-51 Reduced 31.68%	110 $9,000
Q3 2018 Nov 13, 2018	BUY	$93.92 - $105.72 $15,121 - $17,020	161 New	161 $16,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account

Concourse Financial Group Securities, Inc. Biomarin Pharmaceutical Inc Transaction History